Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Emmaus Life Sciences, Inc. (EMMA : OTC)
 
 • Company Description   
Emmaus Life Sciences Inc. is a commercial-stage biopharmaceutical company. It is engaged in the discovery, development, marketing and sale of treatments and therapies, for rare and orphan disease categories. Emmaus Life Sciences Inc., formerly known MYnd Analytics Inc., is based in Torrance, United States.

Number of Employees: 62

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.43 Daily Weekly Monthly
20 Day Moving Average: 23,075 shares
Shares Outstanding: 49.31 (millions)
Market Capitalization: $21.20 (millions)
Beta: 1.98
52 Week High: $2.20
52 Week Low: $0.25
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -45.57% -38.69%
12 Week -70.35% -67.40%
Year To Date -74.25% -68.54%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
21250 HAWTHORNE BOULEVARD SUITE 800
-
TORRANCE,CA 90503
USA
ph: 310-214-0065
fax: 866-294-2611
ir@emmausmedical.com http://www.emmausmedical.com
 
 • General Corporate Information   
Officers
Yutaka Niihara - Chairman and Chief Executive Officer
Willis C. Lee - Chief Operating Officer
Yasushi Nagasaki - Chief Financial Officer
Robert Dickey - Director
Alfred Lui - Director

Peer Information
Emmaus Life Sciences, Inc. (CORR.)
Emmaus Life Sciences, Inc. (RSPI)
Emmaus Life Sciences, Inc. (CGXP)
Emmaus Life Sciences, Inc. (BGEN)
Emmaus Life Sciences, Inc. (GTBP)
Emmaus Life Sciences, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 29137T101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 09/07/22
Share - Related Items
Shares Outstanding: 49.31
Most Recent Split Date: 7.00 (0.17:1)
Beta: 1.98
Market Capitalization: $21.20 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.01 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.00 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 09/07/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 1.15
EPS Growth
vs. Year Ago Period: 82.35%
vs. Previous Quarter: 78.57%
Sales Growth
vs. Year Ago Period: -39.38%
vs. Previous Quarter: 7.09%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -15.66
12/31/21 - -26.33
09/30/21 - -15.26
Current Ratio
03/31/22 - 0.19
12/31/21 - 0.25
09/30/21 - 0.50
Quick Ratio
03/31/22 - -
12/31/21 - 0.13
09/30/21 - 0.25
Operating Margin
03/31/22 - -48.98
12/31/21 - -77.37
09/30/21 - -39.22
Net Margin
03/31/22 - -48.98
12/31/21 - -77.37
09/30/21 - -39.22
Pre-Tax Margin
03/31/22 - -49.50
12/31/21 - -77.25
09/30/21 - -40.91
Book Value
03/31/22 - -0.45
12/31/21 - -0.43
09/30/21 - -0.31
Inventory Turnover
03/31/22 - 0.75
12/31/21 - 0.55
09/30/21 - 0.32
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©